McKesson stock has delivered a very strong 5 year return, yet the current share price of US$853.71 still screens as undervalued on both an intrinsic value estimate using a Discounted Cash Flow (DCF) model and on market multiples.

• McKesson has returned about 3.4x over the past 5 years, which puts long term holders in a very strong position and raises the question of how much upside could reasonably be left.
• Expectations for continued cash flow generation can support the current valuation, while any pressure on margins or reimbursement terms may weigh on what investors are willing to pay for those future cash flows.
• The company looks undervalued on 5 of 6 valuation checks, which means the broader assessment leans cheap rather than fully pricing in its track record and risks.

For investors, the debate is whether McKesson's strong 5 year run and current valuation signals still leave a reasonable margin between market price and intrinsic value.

Does McKesson Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here is built on McKesson’s ability to keep generating meaningful free cash over time. On the latest twelve month figures, McKesson produced about US$6.0b in free cash flow, which the model treats as growing from an already high base rather than relying on a sharp turnaround story. Using a 2 Stage Free Cash Flow to Equity approach, those projected cash flows equate to an estimated intrinsic value of about $1,675 per share.

Set against the current share price of $853.71, the DCF output implies the stock trades at roughly a 49.0% discount to this intrinsic value. That gap suggests the market is valuing McKesson’s future cash generation more conservatively than the model, even after a strong multi year share price run.

On this DCF view, McKesson stock currently screens as materially undervalued according to this model.

Our Discounted Cash Flow (DCF) analysis suggests McKesson is undervalued by 49.0%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.

Is McKesson Still Cheap on Earnings?

P/E is a useful cross check for McKesson because earnings are a key focus for many investors in large, established healthcare distributors. On this measure, McKesson trades on a P/E of about 21.7x, which is slightly below both the Healthcare industry average of around 25.2x and the peer group average of roughly 23.1x.

The tailored fair P/E ratio for McKesson is estimated at about 31.5x, based on factors such as its scale, profitability profile and risk. Compared with the current 21.7x, this suggests the market is assigning a clear discount to what the model indicates might be appropriate for the stock. For investors comparing multiples, that gap implies McKesson could offer earnings at a lower price than both its sector averages and this fair value framework.

On the P/E multiple alone, McKesson stock appears undervalued relative to both industry norms and this fair value estimate.

The McKesson Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for McKesson pick up where this valuation puzzle leaves off by spelling out which assumptions on McKesson's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's share price. Rather than relying on a single multiple or model, each narrative sets out the assumptions behind its view of fair value so you can compare those expectations with McKesson's actual results over time on the Community page.

You can add your voice to the McKesson discussion by sharing a Narrative that lays out your number driven view on the potential direction of its growth, margins and execution. Put your case on record and see how it compares as McKesson's results and share price change over time.

Do you think there's more to the story for McKesson? Head over to our Community to see what others are saying!

The Bottom Line

For McKesson, both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple view indicate an undervalued stock, even after a very strong multi year run. The key question is whether the cash flows that underpin the DCF view and the earnings power implied by the P/E gap can be maintained without meaningful pressure on margins or reimbursement terms. The crux of the debate from here is whether that discount reflects an opportunity for patient investors or a fair cushion for the execution and policy risks that come with McKesson's scale and role in healthcare distribution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.